Abstract: Transgenic mice having a phenotype characterized by the substantial depletion of a mature lymphocytic cell type otherwise naturally occurring in the species from which the transgenic mouse is derived. The phenotype is conferred in the transgenic mouse by a transgene contained in at least the precursor stem cell of the lymphocytic cell type which is depleted. The transgene comprised is a DNA sequence encoding a lymphatic polypeptide variant which inhibits maturation of the lymphocytic cell type.
Type:
Grant
Filed:
December 5, 1996
Date of Patent:
February 8, 2000
Assignee:
GenPharm International
Inventors:
Paulus Jacobus Angelinus Krimpenfort, Antonius Johannes Maria Berns
Abstract: A method of reducing an immune response to a recombinant adenovirus which involves co-administration of the recombinant adenovirus and a selected immune modulator. The immune modulator functions by inhibiting the formation of neutralizing antibodies and/or reducing CTL killing of the virally infected cells. The method additionally encompasses the step of re-administering the recombinant adenovirus.
Type:
Grant
Filed:
February 24, 1995
Date of Patent:
February 16, 1999
Assignees:
The Trustees of the University of Pennsylvania, The Wistar Institute of Anatomy & Biology
Inventors:
James M. Wilson, Yiping Yang, Giorgio Trinchieri
Abstract: A substantially pure DNA comprising a sequence encoding a smooth muscle cell LIM (SmLIM) polypeptide, methods of diagnosing vascular injury by detecting a decrease in SmLIM gene expression, and methods of inhibiting vascular smooth muscle cell proliferation.
Type:
Grant
Filed:
March 15, 1996
Date of Patent:
June 16, 1998
Assignee:
President and Fellows of Harvard College
Inventors:
Mu-En Lee, Edgar Haber, Mukesh Jain, Shaw-Fang Yet
Abstract: Laboratory non-human animals in which the immune system of a donor is induced in and thrives in vivo and expresses the immune response of the donor animal in a recipient non-human animal of a different species than the donor, and wherein malignant immune system cells of the donor can be induced in the recipient non-human animal by injection of non-malignant donor into the recipient are disclosed.
Abstract: Retroviral vectors for directing expression of full length factor VIII in transduced host cells, plasmids encoding the same, and host cells transformed, transfected, or transduced therewith are disclosed. Also disclosed are retroviral particles comprising such retrovital vectors, as are methods for making such particles in suitable packaging cells. Retroviral particles so produced may be amphotropic, ecotropic, polytropic, or xenotropic; alternatively, they may comprise chimeric or hybrid envelope proteins to alter host range. Also described are retrovital particles comprising retroviral vectors for directing full length factor VIII expression which are complement resistant. Pharmaceutical compositions comprising retrovital particles of the invention are also disclosed, as are methods of treating mammals, particularly humans, afflicted with hemophilia.
Type:
Grant
Filed:
December 30, 1994
Date of Patent:
October 28, 1997
Assignee:
Chiron Viagene, Inc.
Inventors:
Mordechai Bodner, Nicholas J. De Polo, Stephen Chang, David Chi-Tang Hsu, James G. Respess
Abstract: Xenogeneic tissue is introduced into an immunocompromised host for interacting with agents and using such interaction for evaluating efficacy of drugs and vaccines, producing xenogeneic monoclonal antibodies, evaluating the effect of the various agents on specific tissues and the like. Particularly, drugs can be evaluated for their efficacy against a wide variety of pathogens which infect xenogeneic tissue, agents can be evaluated for their effect on the xenogeneic immune system and monoclonal antibodies to a predetermined epitope may be produced.
Type:
Grant
Filed:
March 1, 1994
Date of Patent:
June 17, 1997
Assignee:
The Board of Trustees for the Leland Stanford Junior University